利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.018 秒)

    Colorectal cancer prognostics
    21.
    发明申请
    Colorectal cancer prognostics 审中-公开

    公开(公告)号：US20050048494A1

    公开(公告)日：2005-03-03

    申请号：US10651237

    申请日：2003-08-27

    申请人： Yixin Wang

    发明人： Yixin Wang

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118

    摘要： A method of providing a prognosis of colorectal cancer is conducted by analyzing the expression of a group of genes. Gene expresson profiles in a variety of medium such as microarrays are included as are kits that contain them.

    Methods and Materials for Identifying the Origin of a Carcinoma of Unknown Primary Origin
    22.
    发明申请
    Methods and Materials for Identifying the Origin of a Carcinoma of Unknown Primary Origin 审中-公开
    识别原发性原发性癌的原因的方法和材料

    公开(公告)号：US20100021886A1

    公开(公告)日：2010-01-28

    申请号：US12024134

    申请日：2008-02-01

    申请人： YIXIN WANG ,  ABHIJIT MAZUMDER ,  DMITRI TALANTOV ,  TIMOTHY JATKOE ,  JONATHAN F. BADEN

    发明人： YIXIN WANG ,  ABHIJIT MAZUMDER ,  DMITRI TALANTOV ,  TIMOTHY JATKOE ,  JONATHAN F. BADEN

    IPC分类号： C12Q1/68 ,  C12Q1/02 ,  C07H21/00 ,  C40B40/06

    CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/16

    摘要： The present invention provides a method of identifying origin of a metastasis of unknown origin by obtaining a sample containing metastatic cells; measuring Biomarkers associated with at least two different carcinomas; combining the data from the Biomarkers into a linear discrimination analysis where the linear discrimination analysis normalizes the Biomarkers against a reference; and imposes a cut-off which optimizes sensitivity and specificity of each Biomarker, weights the prevalence of the carcinomas and selects a tissue of origin determining origin based on highest probability determined by the linear discrimination analysis or determining that the carcinoma is not derived from a particular set of carcinomas; and optionally measuring Biomarkers specific for one or more additional different carcinoma, and repeating the steps for additional Biomarkers.

    摘要翻译： 本发明提供了通过获得含有转移细胞的样品来鉴定未知来源的转移起点的方法; 测量与至少两种不同癌相关的生物标志物; 将来自生物标志物的数据组合成线性鉴别分析，其中线性鉴别分析使生物标志物反对参考标准化; 并强加了一个优化每个生物标志物的灵敏度和特异性的切断点，重视癌症的流行，并且基于通过线性鉴别分析确定的最高概率来选择确定起源的组织，或者确定癌症不是从特定的 一套癌; 并且任选地测量对一种或多种另外的不同癌特异性的生物标志物，并重复其它生物标志物的步骤。

    Cancer Diagnostic Panel
    23.
    发明申请
    Cancer Diagnostic Panel 审中-公开
    癌症诊断面板

    公开(公告)号：US20090221445A1

    公开(公告)日：2009-09-03

    申请号：US12021439

    申请日：2008-01-29

    申请人： Yixin Wang

    发明人： Yixin Wang

    IPC分类号： C40B40/08

    CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158

    摘要： A method of diagnosing cancer by identifying differential modulation of each gene (relative to the expression of the same genes in a normal population) in a combination of genes selected from two groups of genes.Gene expression portfolios and kits for employing the method are further aspects of the invention.

    摘要翻译： 通过鉴定选自两组基因的基因的组合，通过鉴定每个基因的差异调节（相对于正常群体中的相同基因的表达）来诊断癌症的方法。 用于采用该方法的基因表达组合和试剂盒是本发明的另外的方面。

    Breast cancer prognostics
    24.
    发明申请
    Breast cancer prognostics 审中-公开
    乳腺癌预后

    公开(公告)号：US20050186577A1

    公开(公告)日：2005-08-25

    申请号：US10783271

    申请日：2004-02-20

    申请人： Yixin Wang

    发明人： Yixin Wang

    IPC分类号： C12Q1/68 ,  G01N33/53

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158

    摘要： A method of providing a prognosis of breast cancer is conducted by analyzing the expression of a group of genes. Gene expresson profiles in a variety of medium such as microarrays are included as are kits that contain them.

    摘要翻译： 通过分析一组基因的表达来进行提供乳腺癌预后的方法。 包括微阵列在内的各种培养基中的基因表达谱也包含在其中。

    Colorectal cancer prognostics
    25.
    发明申请
    Colorectal cancer prognostics 审中-公开
    结直肠癌预后

    公开(公告)号：US20050048526A1

    公开(公告)日：2005-03-03

    申请号：US10782413

    申请日：2004-02-18

    申请人： Yixin Wang

    发明人： Yixin Wang

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118

    摘要： A method of providing a prognosis of colorectal cancer is conducted by analyzing the expression of a group of genes. Gene expresson profiles in a variety of medium such as microarrays are included as are kits that contain them.

    摘要翻译： 通过分析一组基因的表达来进行提供结肠直肠癌预后的方法。 包括微阵列在内的各种培养基中的基因表达谱也包含在其中。

    Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
    27.
    发明授权
    Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase 有权
    确定急性骨髓性白血病对法呢基转移酶治疗反应的方法

    公开(公告)号：US07932036B1

    公开(公告)日：2011-04-26

    申请号：US12046902

    申请日：2008-03-12

    申请人： Mitch Raponi ,  Yixin Wang ,  Hongtao Fan

    发明人： Mitch Raponi ,  Yixin Wang ,  Hongtao Fan

    IPC分类号： C12Q1/68 ,  C12P19/34 ,  C07H21/02

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158

    摘要： We analyzed bone marrow from 67 patients from a phase 2 study of farnesyltransferase inhibition with tipifarnib (R115777, ZARNESTRA®), in older adults with previously untreated, poor-risk acute myeloid leukemia (AML) for N-Ras mutations, global gene expression, and/or quantitative PCR (qPCR) of specific genes. Microarray profiling identified a two-gene expression ratio (RASGRP1:APTX) which provided the greatest accuracy for predicting response to tipifarnib. We demonstrated that this classifier could predict response to tipifarnib in an independent set of 54 samples from relapsed or refractory AML, with a NPV and PPV of 92% and 28%, respectively (odds ratio of 4.4). Therefore, in both newly diagnosed and relapsed or refractory AML, this classifier improves the overall response rate by approximately 50% while maintaining a high NPV, and significantly improves patient overall survival. The two-gene classifier was also validated by qPCR in thirty AML samples from the same clinical study demonstrating a negative predictive value (NPV) and positive predictive value (PPV) of 81% and 50%, respectively (odds ratio of 4.3). These data indicate that a simple two-gene expression assay may have utility in diagnosing a population of AML patients who are more likely to respond to tipifarnib.

    摘要翻译： 我们分析了67名来自第二阶段法尼基转移酶抑制研究的替米夫定（R115777，ZARNESTRA？）的老年患者的骨髓，以前未经治疗，低危急性骨髓性白血病（AML），N-Ras突变，全球基因表达， 和/或定量PCR（qPCR）。 微阵列分析鉴定了双基因表达比（RASGRP1：APTX），其提供了对tipifarnib的预测的最大准确度。 我们证明，该分类器可以预测来自复发性或难治性AML的独立54组样本中tipifarnib的反应，NPV和PPV分别为92％和28％（优势比为4.4）。 因此，在新诊断和复发或难治性AML中，该分类器在保持高NPV的同时将总体反应率提高了约50％，并显着提高了患者的总生存期。 来自相同临床研究的三个AML样品中的qPCR也证实了两个基因分类器，分别显示了81％和50％的阴性预测值（NPV）和阳性预测值（PPV）（优势比为4.3）。 这些数据表明，简单的双基因表达测定法可用于诊断更可能对tipifarnib作出反应的AML患者群体。